Trial Profile

Observational study of safety and tolerability of Levemir FlexPen (insulin detemir) in the treatment of type 1 and type 2 diabetes mellitus

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin detemir (Primary)
Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
Focus Adverse reactions
Sponsors Novo Nordisk

Most Recent Events

16 Oct 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
16 Oct 2009 Actual patient number (3299) added as reported by ClinicalTrials.gov.
16 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com